HealthcarePress Releases

Infectious Disease Therapeutics Market Size to Worth Around US$ 167 Billion by 2030

[150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global infectious disease therapeutics market was valued at around USD 115 billion in 2021 and is expected to register revenues worth USD 167 billion by the end of 2030, growing at an exceptional CAGR of approximately 4.23% between 2022 and 2030.

Infectious Disease Therapeutics

Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/2056

Infectious Disease Therapeutics Market Report Scope

A recent study by Precedence Research on the infectious disease therapeutics market offers a forecast for 2022 and 2030. The study analyzes crucial trends that are currently determining the growth of the infectious disease therapeutics market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of infectious disease therapeutics. The study also provides the dynamics that are responsible for influencing the future status of the infectious disease therapeutics market over the forecast period.

A detailed assessment of the infectious disease therapeutics market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the infectious disease therapeutics market along with their product portfolio enhances the reliability of this comprehensive research study.

Competition Landscape

The report has engulfed a chapter on the global infectious disease therapeutics market’s competitive landscape, which provides detailed analysis and insights on companies offering infectious disease therapeutics. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach.

This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.

Read Also@ Metaverse in Healthcare Market Size to Worth Around US$ 72.10 Billion by 2030

Some of the Prominent Players in the Infectious Disease Therapeutics Market Include:
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K)
  • Merck & Co. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • AstraZeneca (U.K)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
Infectious Disease Therapeutics Market Segmentation

By Mode of Treatment

  • Vaccines
  • Drugs

By Target Organism

  • Antifungal
  • Antiviral
  • Antibacterial
  • Anti-parasite
  • Others

By Infection Type

  • Viral
  • Parasitic
  • Fungal
  • Bacterial
  • Others

By Distribution Channel

  • Clinic
  • Hospitals
  • Others

Regional Segmentation

  • Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
  • Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
  • North America [United States, Canada, Mexico]
  • South America [Brazil, Argentina, Columbia, Chile, Peru]
  • Middle East & Africa [GCC, North Africa, South Africa]

Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.

The report provides in-depth segment analysis of the global infectious disease therapeutics market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the infectious disease therapeutics market.

The report includes country-wise and region-wise market size for the period 2022-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2022-2030.

Why should you invest in this report?

If you are aiming to enter the global infectious disease therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for infectious disease therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Infectious Disease Therapeutics Market 

5.1. COVID-19 Landscape: Infectious Disease Therapeutics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Infectious Disease Therapeutics Market, By Mode of Treatment

8.1. Infectious Disease Therapeutics Market, by Mode of Treatment, 2022-2030

8.1.1. Vaccines

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Drugs

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Infectious Disease Therapeutics Market, By Target Organism

9.1. Infectious Disease Therapeutics Market, by Target Organism e, 2022-2030

9.1.1. Antifungal

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Antiviral

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Antibacterial

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Anti-parasite

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Infectious Disease Therapeutics Market, By Infection Type 

10.1. Infectious Disease Therapeutics Market, by Infection Type, 2022-2030

10.1.1. Viral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Parasitic

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Fungal

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Bacterial

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Infectious Disease Therapeutics Market, By Distribution Channel 

11.1. Infectious Disease Therapeutics Market, by Distribution Channel, 2022-2030

11.1.1. Clinic

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Avastin

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Hospitals

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Infectious Disease Therapeutics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.1.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.1.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.2.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.2.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.3.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.3.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.4.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.4.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Pfizer Inc. (U.S.)

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GlaxoSmithKline plc. (U.K)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Merck & Co. (U.S.)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. F. Hoffmann-La Roche Ltd (Switzerland)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca (U.K)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Mylan N.V. (U.S.)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Novartis AG (Switzerland)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Sanofi (France)

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/2056

About Us

Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.

From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.

Contact Us:                  

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Show More

Janet Edward

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

Related Articles

Back to top button